Should I buy or sell BELLUS Health stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLU shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLU, but not buy additional shares or sell existing shares. View BLU analyst ratings or view top-rated stocks .

What is BELLUS Health's stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for BELLUS Health's stock. Their BLU share price targets range from $14.75 to $14.75. On average, they predict the company's stock price to reach $14.75 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View analysts price targets for BLU or view top-rated stocks among Wall Street analysts .

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG) , Party City Holdco (PRTY) , Washington Prime Group (WPG) , Akorn (AKRXQ) , Akers Biosciences (AKER) , Akebia Therapeutics (AKBA) , Adamis Pharmaceuticals (ADMP) , ADMA Biologics (ADMA) and Acasti Pharma (ACST) .

NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BLU Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $14.74
▼
$14.75
50-Day Range: $14.42
▼
$14.75
52-Week Range: $6.38
▼
$14.76

Volume: 3.45 million shs
Average Volume: 3.08 million shs
Market Capitalization: $1.87 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.75

Stock Analysis

Get BELLUS Health alerts:

BELLUS Health MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 0.1% Upside
$14.75 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.97) to ($1.00) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.07 out of 5 stars

Medical Sector

911th out of 918 stocks

Biotechnology Industry

42nd out of 43 stocks

1.0

Analyst's Opinion

Consensus Rating
BELLUS Health has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
BELLUS Health has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BLU.

0.0

Dividend Strength

Dividend Yield
BELLUS Health does not currently pay a dividend.
Dividend Growth
BELLUS Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLU.

0.6

News and Social Media Coverage

Search Interest
2 people have searched for BLU on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BELLUS Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.17% of the stock of BELLUS Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.37% of the stock of BELLUS Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for BELLUS Health are expected to decrease in the coming year, from ($0.97) to ($1.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BELLUS Health is -20.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BELLUS Health is -20.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BELLUS Health has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About BELLUS Health Stock (NASDAQ:BLU)

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

BLU Stock News Headlines

March 21, 2024 | msn.com

Deal reached between Dignity Health, Arizona Blue Cross Blue Shield

March 4, 2024 | msn.com

The effects of 'blue light' on human health are still unclear, says panel

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 4, 2024 | msn.com

Glowing blue waves off Orange County coast make for thrilling start to New Year

December 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Bluebird Bio (BLUE), United Therapeutics (UTHR)

September 21, 2023 | forbes.com

CBD Dosage: How Much Should You Take?

June 28, 2023 | fool.com

Bellus Health (NASDAQ: BLU)

June 27, 2023 | msn.com

These Canadian Biotech Stocks Are Quietly Changing the Face of Healthcare

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

June 25, 2023 | finance.yahoo.com

BLU.TO - BELLUS Health Inc.

June 17, 2023 | markets.businessinsider.com

BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)

May 10, 2023 | ca.finance.yahoo.com

TSX Stocks in the Healthcare Industry: Which Ones Are Worth Your Money?

May 10, 2023 | finance.yahoo.com

Should You Buy Bellus Health (BLU) After Golden Cross?

May 2, 2023 | theglobeandmail.com

Closing Bell: Bellus Health Inc up on Tuesday (BLU)

April 26, 2023 | theglobeandmail.com

BELLUS Health: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (BLU)

April 26, 2023 | finance.yahoo.com

BELLUS Health Announces Meeting Updates

April 21, 2023 | benzinga.com

Moore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law Firm

April 19, 2023 | finance.yahoo.com

Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

April 19, 2023 | theglobeandmail.com

GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family

April 19, 2023 | reuters.com

GSK bets $2 bln on Bellus cough drug to soothe pipeline fears

April 18, 2023 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)

April 18, 2023 | theglobeandmail.com

GSK signs deal to buy Canadian drug developer Bellus Health for US$2 billion

April 18, 2023 | finance.yahoo.com

Bellus Health Soars 99% As GSK Joins Buyout Bonanza With $2 Billion Deal

April 18, 2023 | cnbc.com

Stocks making the biggest moves midday: Southwest Airlines, Goldman Sachs, Bellus Health and more

April 18, 2023 | bizjournals.com

GSK to buy Canadian biopharm firm Bellus Health for $2 billion

April 18, 2023 | finance.yahoo.com

Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal

April 18, 2023 | finance.yahoo.com

Why BELLUS Health Stock Is Rocketing Higher Today

See More Headlines

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BLU
CUSIP: N/A
CIK: 1259942
Web: www.bellushealth.com
Phone: (450) 680-4500
Fax: 45-0680-4501
Employees: 74
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.75
High Stock Price Target: $14.75
Low Stock Price Target: $14.75
Potential Upside/Downside: +0.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,080,000.00
Net Margins: -578,586.63%
Pretax Margin: -578,226.56%
Return on Equity: -24.27%
Return on Assets: -23.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 33.42
Quick Ratio: 33.42

Sales & Book Value

Annual Sales: $15,000.00
Price / Sales: 124,613.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.09 per share
Price / Book: 4.77

Miscellaneous

Outstanding Shares: 126,812,000
Free Float: 96,162,000
Market Cap: $1.87 billion
Optionable: Not Optionable
Beta: 0.19

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Roberto Francesco Bellini (Age 43)
Pres, CEO & Director
Comp: $790.35k
Mr. Ramzi Benamar (Age 50)
Chief Financial Officer
Comp: $650.48k
Dr. Andreas Orfanos FFPM (Age 64)
M.B.B.Ch, MBA, Chief Operating Officer
Comp: $417.58k
Dr. Denis Garceau Ph.D. (Age 66)
Chief Scientific Officer
Comp: $496.56k
Dr. Catherine M. Bonuccelli M.D. (Age 65)
Chief Medical Officer
Comp: $741.66k
Mr. Daniel Matthews
Director of Investor Relations & Communications
Mr. Tony Matzouranis (Age 50)
Chief Bus. Officer
Mr. Sebastien Roy (Age 47)
Corp. Sec.

Key Competitors

View All Competitors

BLU Stock Analysis - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLU shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLU, but not buy additional shares or sell existing shares.
View BLU analyst ratings or view top-rated stocks.
What is BELLUS Health's stock price target for 2024?: 1 equities research analysts have issued 1-year price objectives for BELLUS Health's stock. Their BLU share price targets range from $14.75 to $14.75. On average, they predict the company's stock price to reach $14.75 in the next year. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for BLU or view top-rated stocks among Wall Street analysts.
How were BELLUS Health's earnings last quarter?: BELLUS Health Inc. (NASDAQ:BLU) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.
What other stocks do shareholders of BELLUS Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

This page (NASDAQ:BLU) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BELLUS Health (BLU) Stock Price, News & Analysis

BELLUS Health MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About BELLUS Health Stock (NASDAQ:BLU)

BLU Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BLU Stock Analysis - Frequently Asked Questions

Overall MarketRank^™